반응식
C(OC([N:8]1[CH2:14][CH2:13][CH2:12][N:11]([C:15]2[N:16]=[CH:17][C:18]([C:21]([NH:23][C:24]3[CH:39]=[CH:38][C:37]([F:40])=[CH:36][C:25]=3[C:26]([NH:28][C:29]3[CH:34]=[CH:33][C:32]([Cl:35])=[CH:31][N:30]=3)=[O:27])=[O:22])=[N:19][CH:20]=2)[CH2:10][CH2:9]1)=O)(C)(C)C.FC(F)(F)C(O)=O>C(Cl)Cl.C1(OC)C=CC=CC=1>[F:40][C:37]1[CH:38]=[CH:39][C:24]([NH:23][C:21]([C:18]2[CH:17]=[N:16][C:15]([N:11]3[CH2:12][CH2:13][CH2:14][NH:8][CH2:9][CH2:10]3)=[CH:20][N:19]=2)=[O:22])=[C:25]([CH:36]=1)[C:26]([NH:28][C:29]1[CH:34]=[CH:33][C:32]([Cl:35])=[CH:31][N:30]=1)=[O:27]참가 물질
5
반응물 2
생성물 1
시약·촉매·용매 2
실험 절차
To a suspension of 2-[5-(4-t-butoxycarbonylhexahydro-1,4-diazepin-1-yl)pyrazin-2-ylcarbonylamino]-5-fluoro-N-(5-chloropyridin-2-yl)benzamide (Example P1, 11.4 g) in methylene chloride (30 mL) and anisole (10 mL) was added trifluoroacetic acid (30 mL) dropwise. The mixture was stirred overnight at room temperature before the solvent was evaporated. The residue was purified by using an SCX column. Yield 8.1 g.
후처리
- customwas evaporated
- customThe residue was purified
출처 및 근거
- ORD 기록
- ord-6a6db8c1d7d345a7925ee6236819d89b
- 출처 데이터셋
- uspto-grants-2007_01
- 특허 번호
- US07160878B2
연결된 노트
불러오는 중…